Stockscreener 앱 받기
0.50
0.00%
0.00
시간 외 거래:
.49
-0.01
-2.00%
전일 마감가:
$0.50
열려 있는:
$0.4889
하루 거래량:
1.64M
Relative Volume:
0.48
시가총액:
$11.18M
수익:
-
순이익/손실:
$-22.79M
주가수익비율:
-0.2971
EPS:
-1.6827
순현금흐름:
$-15.11M
1주 성능:
+0.00%
1개월 성능:
-54.55%
6개월 성능:
-81.95%
1년 성능:
-83.92%
1일 변동 폭
$0.4801
$0.532
1주일 범위
$0.4801
$0.5792
52주 변동 폭
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.50 | 11.18M | 0 | -22.79M | -15.11M | -1.6827 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Analyst Calls: Is Medicus Pharma Ltd exposed to currency risks2026 Price Swings & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to host fireside chat on SkinJect trial results By Investing.com - Investing.com South Africa
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Medicus Pharma Ltd outperform the market in YEARDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Medicus Pharma prices $7 million share offering - MSN
Medicus Pharma on Bloomberg World - Journal & Courier
Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat - TipRanks
Medicus Pharma to host fireside chat on SkinJect trial results - Investing.com
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst - standard-journal.com
Microneedle therapy cleared 73% of basal cell lesions, may help patients avoid surgery - Stock Titan
Aug Sectors: What is the dividend yield of Medicus Pharma Ltd Equity Warrant2026 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Medicus Pharma schedules webcast on basal cell carcinoma study By Investing.com - Investing.com India
Aug Opening: Is Medicus Pharma Ltd Equity Warrant a speculative investment2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Medicus reports phase 2 results for SkinJect basal cell carcinoma study - MSN
Investment Recap: Can Medicus Pharma Ltd sustain its profitabilityTrade Exit Report & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to highlight positive Phase 2 SkinJect data during webcast with lead investigator - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Data Ahead of Business Update Call - TipRanks
Medicus Pharma schedules webcast on basal cell carcinoma study - Investing.com
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 - ChartMill
Medicus Pharma CEO discusses promising Phase 2 SkinJect resultsICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary with Opening Bell Ceremony - The Globe and Mail
Medicus Pharma reports positive phase 2 results for SkinJect skin cancer therapy - MSN
Risk Report: Will Medicus Pharma Ltd outperform the market in YEAR2026 Update & High Accuracy Investment Signals - baoquankhu1.vn
Medicus Pharma receives FDA clearance to begin Phase 2b Teverelix study - MSN
Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum - The Globe and Mail
Medicus Pharma reports phase 2 results for basal cell carcinoma therapy - MSN
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy - MyChesCo
Medicus Pharma to spotlight AI-driven drug development at Longwood Miami CEO Forum - Proactive financial news
Medicus Pharma to Showcase AI-Enabled Drug Development at Longwood Miami CEO Forum - National Today
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum - News-Press NOW
Faster, cheaper trials: Medicus Pharma brings AI strategy to Miami forum - Stock Titan
Medicus Pharma to Present Drug Development Programs at Roth Conference - MyChesCo
MDCX Maintains Buy Rating with Stable Price Target | MDCX Stock News - GuruFocus
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive financial news
Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma - TipRanks
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer - Proactive financial news
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset - The Manila Times
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset - Bitget
Aug Ideas: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture - The Globe and Mail
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.99%
자본화:
|
볼륨(24시간):